We serve Chemical Name:3-Methyl-3-nonanol CAS:21078-72-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Methyl-3-nonanol
CAS.NO:21078-72-8
Synonyms:MFCD00046612;3-Nonanol, 3-methyl-;3-methyl-nonan-3-ol;3-Nonanol,3-methyl;Methyl-aethyl-hexyl-carbinol;3-Methyl-3-nonanol;methyl-ethyl-hexyl-carbinol;2-Ethyl-octan-2-ol;3-Methylnonan-3-ol;EINECS 244-195-2
Molecular Formula:C10H22O
Molecular Weight:158.281
HS Code:
Physical and Chemical Properties:
Melting point:149-151 °C(lit.)
Boiling point:201.3±8.0 °C at 760 mmHg
Density:0.8±0.1 g/cm3
Index of Refraction:1.435
PSA:20.23000
Exact Mass:158.167068
LogP:3.70
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like MFCD00046612 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 244-195-2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00046612 Use and application,3-Nonanol,3-methyl technical grade,usp/ep/jp grade.
Related News: ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. 3-Methyl-3-nonanol manufacturer In addition, although the API and intermediate industries are capital-intensive and technology-intensive industries, new competitors are still joining. 3-Methyl-3-nonanol supplier Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. 3-Methyl-3-nonanol vendor Featured APIs: Production capacity continues to expand, targeted patents expire. Original research drugs: industry entry barriers are high, performance stability and certainty are high. 3-Methyl-3-nonanol factory To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early.